Stem cells for the treatment of heart failure

Current Research in Translational Medicine

Volumn 64, Issue 2, 2016, Pages 97-106

  Menasche P ^a,b,c   Vanneaux, V ^d,e  

^a HÔPITAL EUROPÉEN GEORGES POMPIDOU   (France)

^b UNIVERSITÉ PARIS DESCARTES   (France)

^c PARIS CARDIOVASCULAR RESEARCH CENTER   (France)

^d INSERM   (France)

^e SAINT LOUIS HOSPITAL   (France)

Author keywords

Cell therapy; Heart failure; Stem cells

Indexed keywords

BIOMATERIAL; MICRORNA; SIGNAL PEPTIDE;

ALLOGENEIC STEM CELL TRANSPLANTATION; CARDIAC MUSCLE; CARDIAC MUSCLE CELL; CARDIAC STEM CELL; CELL DIFFERENTIATION; CELL SPECIFICITY; CELL SURVIVAL; CLINICAL PRACTICE; COST EFFECTIVENESS ANALYSIS; EMBRYONIC STEM CELL; ENGRAFTMENT; HEART FAILURE; HUMAN; IMMUNOMODULATION; LABORATORY AUTOMATION; PARACRINE SIGNALING; PHENOTYPIC VARIATION; PLURIPOTENT STEM CELL; QUALITY CONTROL PROCEDURES; REVIEW; SCALE UP; STEM CELL TRANSPLANTATION; TISSUE ENGINEERING; TISSUE REPAIR; TREATMENT INDICATION; ALLOGRAFT; ANIMAL; CELL SEPARATION; CYTOLOGY; ECONOMICS; EXOSOME; GRAFT SURVIVAL; MOUSE; PHYSIOLOGY; PROCEDURES; RANDOMIZED CONTROLLED TRIAL (TOPIC); SECRETION (PROCESS); STEM CELL; TERATOMA; TRANSPLANTATION;

ALLOGRAFTS; ANIMALS; CELL SEPARATION; EMBRYONIC STEM CELLS; EXTRACELLULAR VESICLES; GRAFT SURVIVAL; HEART FAILURE; HUMANS; INTERCELLULAR SIGNALING PEPTIDES AND PROTEINS; MICE; MICRORNAS; MYOCARDIUM; MYOCYTES, CARDIAC; PARACRINE COMMUNICATION; PLURIPOTENT STEM CELLS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; STEM CELL TRANSPLANTATION; STEM CELLS; TERATOMA; TISSUE ENGINEERING;

EID: 84999104963     PISSN: None     EISSN: 24523186     Source Type: Journal    
DOI: 10.1016/j.retram.2016.04.003     Document Type: Review

References (123)

1. Fisher, S.A., Doree, C., Mathur, A., Martin-Rendon, E., Meta-analysis of cell therapy trials for patients with heart failure – an update. Circ Res 116 (2015), 1361–1377.
2. Kandala, J., Upadhyay, G.A., Pokushalov, E., Wu, S., Drachman, D.E., Singh, J.P., Meta-analysis of stem cell therapy in chronic ischemic cardiomyopathy. Am J Cardiol 112 (2013), 217–225.
3. Menasché P., Cardiac cell therapy: lessons from clinical trials. J Mol Cell Cardiol 50 (2011), 258–265.
4. Garbern, J.C., Lee, R.T., Cardiac stem cell therapy and the promise of heart regeneration. Cell Stem Cell 12 (2013), 689–698.
5. den Haan, M.C., Grauss, R.W., Smits, A.M., Winter, E.M., van Tuyn, J., Pijnappels, D.A., et al. Cardiomyogenic differentiation-independent improvement of cardiac function by human cardiomyocyte progenitor cell injection in ischaemic mouse hearts. J Cell Mol Med 16 (2012), 1508–1521.
6. Gerbin, K.A., Yang, X., Murry, C.E., Coulombe, K.L., Enhanced electrical integration of engineered human myocardium via intramyocardial versus epicardial delivery in infarcted rat hearts. PLoS One, 10, 2015, e0131446.
7. Bergmann, O., Zdunek, S., Felker, A., Salehpour, M., Alkass, K., Bernard, S., et al. Dynamics of cell generation and turnover in the human heart. Cell 161 (2015), 1566–1575.
8. Burt, R.K., Chen, Y., Verda, L., Lucena, C., Navale, S., Johnson, J., et al. Mitotically inactivated embryonic stem cells can be used as an in vivo feeder layer to nurse damaged myocardium after acute myocardial infarction: a preclinical study. Circ Res 111 (2012), 1286–1296.
9. Mathivanan, S., Fahner, C.J., Reid, G.E., Simpson, R.J., ExoCarta 2012: database of exosomal proteins, RNA and lipids. Nucleic Acids Res 40:Database issue (2012), D1241–D1244.
10. Bobis-Wozowicz, S., Kmiotek, K., Sekula, M., Kedracka-Krok, S., Kamycka, E., Adamiak, M., et al. Human induced pluripotent stem cell-derived microvesicles transmit RNAs and proteins to recipient mature heart cells modulating cell fate and behavior. Stem Cells, 2015, 10.1002/stem.2078 [Epub ahead of print].
11. Tseliou, E., Fouad, J., Reich, H., Slipczuk, L., de Couto, G., Aminzadeh, M., et al. Fibroblasts rendered antifibrotic, antiapoptotic, and angiogenic by priming with cardiosphere-derived extracellular membrane vesicles. J Am Coll Cardiol 66 (2015), 599–611.
12. Akyurekli, C., Le, Y., Richardson, R.B., Fergusson, D., Tay, J., Allan, D.S., A systematic review of preclinical studies on the therapeutic potential of mesenchymal stromal cell-derived microvesicles. Stem Cell Rev 11 (2015), 150–160.
13. Barile, L., Lionetti, V., Cervio, E., Matteucci, M., Gherghiceanu, M., Popescu, L.M., et al. Extracellular vesicles from human cardiac progenitor cells inhibit cardiomyocyte apoptosis and improve cardiac function after myocardial infarction. Cardiovasc Res 103 (2014), 530–541.
14. Ibrahim, A.G.-E., Cheng, K., Marbán, E., Exosomes as critical agents of cardiac regeneration triggered by cell therapy. Stem Cell Reports 2 (2014), 606–619.
15. Khan, M., Nickoloff, E., Abramova, T., Johnson, J., Verma, S.K., Krishnamurthy, P., et al. Embryonic stem cell-derived exosomes promote endogenous repair mechanisms and enhance cardiac function following myocardial infarction. Circ Res 117 (2015), 52–64.
16. Seeger, F.H., Zeiher, A.M., Dimmeler, S., MicroRNAs in stem cell function and regenerative therapy of the heart. Arterioscler Thromb Vasc Biol 33 (2013), 1739–1746.
17. Gray, W.D., French, K.M., Ghosh-Choudhary, S., Maxwell, J.T., Brown, M.E., Platt, M.O., et al. Identification of therapeutic covariant microRNA clusters in hypoxia-treated cardiac progenitor cell exosomes using systems biology. Circ Res 116 (2015), 255–263.
18. Yuan, A., Farber, E.L., Rapoport, A.L., Tejada, D., Deniskin, R., Akhmedov, N.B., et al. Transfer of microRNAs by embryonic stem cell microvesicles. PLoS One, 4(3), 2009, e4722.
19. Cheng, K., Malliaras, K., Smith, R.R., Shen, D., Sun, B., Blusztajn, A., et al. Human cardiosphere-derived cells from advanced heart failure patients exhibit augmented functional potency in myocardial repair. JACC Heart Fail 2 (2014), 49–61.
20. Canseco, D.C., Kimura, W., Garg, S., Mukherjee, S., Bhattacharya, S., Abdisalaam, S., et al. Human ventricular unloading induces cardiomyocyte proliferation. J Am Coll Cardiol 65 (2015), 892–900.
21. Ebelt, H., Jungblut, M., Zhang, Y., Kubin, T., Kostin, S., Technau, A., et al. Cellular cardiomyoplasty: improvement of left ventricular function correlates with the release of cardioactive cytokines. Stem Cells 25 (2007), 236–244.
22. Matsuura, K., Honda, A., Nagai, T., Fukushima, N., Iwanaga, K., Tokunaga, M., et al. Transplantation of cardiac progenitor cells ameliorates cardiac dysfunction after myocardial infarction in mice. J Clin Invest 119 (2009), 2204–2217.
23. Tokunaga, M., Liu, M.L., Nagai, T., Iwanaga, K., Matsuura, K., Takahashi, T., et al. Implantation of cardiac progenitor cells using self-assembling peptide improves cardiac function after myocardial infarction. J Mol Cell Cardiol 49 (2010), 972–983.
24. Rossini, A., Frati, C., Lagrasta, C., Graiani, G., Scopece, A., Cavalli, S., et al. Human cardiac and bone marrow stromal cells exhibit distinctive properties related to their origin. Cardiovasc Res 89 (2011), 650–660.
25. Oskouei, B.N., Lamirault, G., Joseph, C., Treuer, A.V., Landa, S., Da Silva, J., et al. Increased potency of cardiac stem cells compared with bone marrow mesenchymal stem cells in cardiac repair. Stem Cells Transl Med 1 (2012), 116–124.
26. Li, T.S., Cheng, K., Malliaras, K., Smith, R.R., Zhang, Y., Sun, B., et al. Direct comparison of different stem cell types and subpopulations reveals superior paracrine potency and myocardial repair efficacy with cardiosphere-derived cells. J Am Coll Cardiol 59 (2012), 942–953.
27. Zheng, S.X., Weng, Y.L., Zhou, C.Q., Wen, Z.Z., Huang, H., Wu, W., et al. Comparison of cardiac stem cells and mesenchymal stem cells transplantation on the cardiac electrophysiology in rats with myocardial infarction. Stem Cell Rev 9 (2013), 339–349.
28. Citro, L., Naidu, S., Hassan, F., Kuppusamy, M.L., Kuppusamy, P., Angelos, M.G., et al. Comparison of human induced pluripotent stem-cell derived cardiomyocytes with human mesenchymal stem cells following acute myocardial infarction. PLoS One, 9, 2014, e116281.
29. Liu, M.L., Nagai, T., Tokunaga, M., Iwanaga, K., Matsuura, K., Takahashi, T., et al. Anti-inflammatory peptides from cardiac progenitors ameliorate dysfunction after myocardial infarction. J Am Heart Assoc, 3, 2014, e001101.
30. Noseda, M., Abreu-Paiva, M., Schneider, M.D., The quest for the adult cardiac stem cell. Circ J 79 (2015), 1422–1430.
31. Malliaras, K., Makkar, R.R., Smith, R.R., Cheng, K., Wu, E., Bonow, R.O., et al. Intracoronary cardiosphere-derived cells after myocardial infarction: evidence of therapeutic regeneration in the final 1-year results of the CADUCEUS trial (CArdiosphere-Derived aUtologous stem CElls to reverse ventricUlar dySfunction). J Am Coll Cardiol 63 (2014), 110–122.
32. Takehara, N., Ogata, T., Nakata, M., Kami, D., Nakamura, T., Matoba, S., et al. The ALCADIA (Autologous Human Cardiac-Derived Stem cell To Treat Ischemic Cardiomyopathy) trial (Abstract). Circulation 126 (2012), 2776–2799.
33. Ishigami, S., Ohtsuki, S., Tarui, S., Ousaka, D., Eitoku, T., Kondo, M., et al. Intracoronary autologous cardiac progenitor cell transfer in patients with hypoplastic left heart syndrome: the TICAP prospective phase 1 controlled trial. Circ Res 116 (2015), 653–664.
34. Chugh, A.R., Beache, G.M., Loughran, J.H., Mewton, N., Elmore, J.B., Kajstura, J., et al. Administration of cardiac stem cells in patients with ischemic cardiomyopathy: the SCIPIO trial: surgical aspects and interim analysis of myocardial function and viability by magnetic resonance. Circulation 126:11 Suppl. 1 (2012), S54–S64.
35. van Berlo, J.H., Kanisicak, O., Maillet, M., Vagnozzi, R.J., Karch, J., Lin, S.C., et al. c-kit+ cells minimally contribute cardiomyocytes to the heart. Nature 509 (2014), 337–341.
36. Blin, G., Nury, D., Stefanovic, S., Neri, T., Guillevic, O., Brinon, B., et al. A purified population of multipotent cardiovascular progenitors derived from primate pluripotent stem cells engrafts in postmyocardial infarcted nonhuman primates. J Clin Invest 120 (2010), 1125–1139.
37. Chong, J.J., Yang, X., Don, C.W., Minami, E., Liu, Y.W., Weyers, J.J., et al. Human embryonic-stem-cell-derived cardiomyocytes regenerate non-human primate hearts. Nature 510 (2014), 273–277.
38. Laflamme, M.A., Chen, K.Y., Naumova, A.V., Muskheli, V., Fugate, J.A., Dupras, S.K., et al. Cardiomyocytes derived from human embryonic stem cells in pro-survival factors enhance function of infarcted rat hearts. Nat Biotechnol 25 (2007), 1015–1024.
39. van Laake, L.W., Passier, R., den Ouden, K., Schreurs, C., Monshouwer-Kloots, J., Ward-van Oostwaard, D., et al. Improvement of mouse cardiac function by hESC-derived cardiomyocytes correlates with vascularity but not graft size. Stem Cell Res 3 (2009), 106–112.
40. Yeghiazarians, Y., Gaur, M., Zhang, Y., Sievers, R.E., Ritner, C., Prasad, M., et al. Myocardial improvement with human embryonic stem cell-derived cardiomyocytes enriched by p38MAPK inhibition. Cytotherapy 14 (2012), 223–231.
41. Moon, S.-H., Kang, S.-W., Park, S.-J., Bae, D., Kim, S.J., Lee, H.-A., et al. The use of aggregates of purified cardiomyocytes derived from human ESCs for functional engraftment after myocardial infarction. Biomaterials 34 (2013), 4013–4026.
42. Menasché P., Vanneaux, V., Fabreguettes, J.R., Bel, A., Tosca, L., Garcia, S., Towards a clinical use of human embryonic stem cell-derived cardiac progenitors: a translational experience. Eur Heart J, 2014 pii: ehu192 [Epub ahead of print].
43. Abbasalizadeh, S., Baharvand, H., Technological progress and challenges towards cGMP manufacturing of human pluripotent stem cells based therapeutic products for allogeneic and autologous cell therapies. Biotechnol Adv 31 (2013), 1600–1623.
44. Parikh, A., Wu, J., Blanton, R.M., Tzanakakis, E.S., Signaling pathways and gene regulatory networks in cardiomyocyte differentiation. Tissue Eng Part B Rev 21 (2015), 377–392.
45. Mummery, C.L., Zhang, J., Ng, E.S., Elliott, D.A., Elefanty, A.G., Kamp, T.J., Differentiation of human embryonic stem cells and induced pluripotent stem cells to cardiomyocytes: a methods overview. Circ Res 111 (2012), 344–358.
46. Genead, R., Danielsson, C., Andersson, A.B., Corbascio, M., Franco-Cereceda, A., Sylvén, C., et al. Islet-1 cells are cardiac progenitors present during the entire lifespan: from the embryonic stage to adulthood. Stem Cells Dev 19 (2010), 1601–1615.
47. Lian, X., Bao, X., Zilberter, M., Westman, M., Fisahn, A., Hsiao, C., et al. Chemically defined, albumin-free human cardiomyocyte generation. Nat Methods 12 (2015), 595–596.
48. Ye, J., Gaur, M., Zhang, Y., Sievers, R.E., Woods, B.J., Aurigui, J., et al. Treatment with hESC-derived myocardial precursors improves cardiac function after a myocardial infarction. PLoS One, 7, 2015, e0131123.
49. Rao, C., Prodromakis, T., Kolker, L., Chaudhry, U.A.R., Trantidou, T., Sridhar, A., et al. The effect of microgrooved culture substrates on calcium cycling of cardiac myocytes derived from human induced pluripotent stem cells. Biomaterials 34 (2013), 2399–2411.
50. Guilak, F., Cohen, D.M., Estes, B.T., Gimble, J.M., Liedtke, W., Chen, C.S., Control of stem cell fate by physical interactions with the extracellular matrix. Cell Stem Cell 5 (2009), 17–26.
51. Lee, A.S., Tang, C., Rao, M.S., Weissman, I.L., Wu, J.C., Tumorigenicity as a clinical hurdle for pluripotent stem cell therapies. Nat Med 19 (2013), 998–1004.
52. Tang, C., Lee, A.S., Volkmer, J.P., Sahoo, D., Nag, D., Mosley, A.R., et al. An antibody against SSEA-5 glycan on human pluripotent stem cells enables removal of teratoma-forming cells. Nat Biotechnol 29 (2011), 829–834.
53. Tohyama, S., Hattori, F., Sano, M., Hishiki, T., Nagahata, Y., Matsuura, T., et al. Distinct metabolic flow enables large-scale purification of mouse and human pluripotent stem cell-derived cardiomyocytes. Cell Stem Cell 12 (2013), 127–137.
54. Smith, A.J., Nelson, N.G., Oommen, S., Hartjes, K.A., Folmes, C.D., Terzic, A., et al. Apoptotic susceptibility to DNA damage of pluripotent stem cells facilitates pharmacologic purging of teratoma risk. Stem Cells Transl Med 1 (2012), 709–718.
55. Tateno, H., Onuma, Y., Ito, Y., Minoshima, F., Saito, S., Shimizu, M., et al. Elimination of tumorigenic human pluripotent stem cells by a recombinant lectin-toxin fusion protein. Stem Cell Reports 4 (2015), 811–820.
56. Loh, K.M., Lim, B., A precarious balance: pluripotency factors as lineage specifiers. Cell Stem Cell 8 (2011), 363–369.
57. Stefanovic, S., Pucéat, M., Oct-3/4: not just a gatekeeper of pluripotency for embryonic stem cell, a cell fate instructor through a gene dosage effect. Cell Cycle 6 (2007), 8–10.
58. Behfar, A., Hodgson, D.M., Zingman, L.V., Perez-Terzic, C., Yamada, S., Kane, G.C., et al. Administration of allogenic stem cells dosed to secure cardiogenesis and sustained infarct repair. Ann N Y Acad Sci 1049 (2005), 189–198.
59. Tomescot, A., Leschik, J., Bellamy, V., Dubois, G., Messas, E., Bruneval, P., et al. Differentiation in vivo of cardiac committed human embryonic stem cells in postmyocardial infarcted rats. Stem Cells 25 (2007), 2200–2205.
60. Bel, A., Planat-Bernard, V., Saito, A., Bonnevie, L., Bellamy, V., Sabbah, L., et al. Composite cell sheets: a further step toward safe and effective myocardial regeneration by cardiac progenitors derived from embryonic stem cells. Circulation 122 (2010), S118–S123.
61. Bellamy, V., Vanneaux, V., Bel, A., Nemetalla, H., Emmanuelle Boitard, S., Farouz, Y., et al. Long-term functional benefits of human embryonic stem cell-derived cardiac progenitors embedded into a fibrin scaffold. J Heart Lung Transplant 34 (2015), 1198–1207.
62. Oliveira, P.H., da Silva, C.L., Cabral, J.M., Concise review: genomic instability in human stem cells: current status and future challenges. Stem Cells 32 (2014), 2824–2832.
63. Menasché P., Vanneaux, V., Hagège, A., Bel, A., Cholley, B., Cacciapuoti, I., et al. Human embryonic stem cell-derived cardiac progenitors for severe heart failure treatment: first clinical case report. Eur Heart J 36 (2015), 2011–2017.
64. Schwartz, S.D., Regillo, C.D., Lam, B.L., Eliott, D., Rosenfeld, P.J., Gregori, N.Z., et al. Human embryonic stem cell-derived retinal pigment epithelium in patients with age-related macular degeneration and Stargardt's macular dystrophy: follow-up of two open-label phase 1/2 studies. Lancet 385 (2015), 509–516.
65. Bartunek, J., Behfar, A., Dolatabadi, D., Vanderheyden, M., Ostojic, M., Dens, J., et al. Cardiopoietic stem cell therapy in heart failure: the C-CURE (Cardiopoietic stem Cell therapy in heart failURE) multicenter randomized trial with lineage-specified biologics. J Am Coll Cardiol 61 (2013), 2329–2338.
66. Mathiasen, A.B., Qayyum, A.A., Jørgensen, E., Helqvist, S., Fischer-Nielsen, A., Kofoed, K.F., et al. Bone marrow-derived mesenchymal stromal cell treatment in patients with severe ischaemic heart failure: a randomized placebo-controlled trial (MSC-HF trial). Eur Heart J 36 (2015), 1744–1753.
67. Nguyen, P.K., Riegler, J., Wu, J.C., Stem cell imaging: from bench to bedside. Cell Stem Cell 14 (2014), 431–444.
68. Lang, C., Lehner, S., Todica, A., Boening, G., Zacherl, M., Franz, W.M., et al. In-vivo comparison of the acute retention of stem cell derivatives and fibroblasts after intramyocardial transplantation in the mouse model. Eur J Nucl Med Mol Imaging 41 (2014), 2325–2336.
69. Mohsin, S., Siddiqi, S., Collins, B., Sussman, M.A., Empowering adult stem cells for myocardial regeneration. Circ Res 109 (2011), 1415–1428.
70. Levit, R.D., Landázuri, N., Phelps, E.A., Brown, M.E., García, A.J., Davis, M.E., et al. Cellular encapsulation enhances cardiac repair. J Am Heart Assoc, 2(5), 2013, e000367.
71. Freyman, T., Polin, G., Osman, H., Crary, J., Lu, M., Cheng, L., et al. A quantitative, randomized study evaluating three methods of mesenchymal stem cell delivery following myocardial infarction. Eur Heart J 27 (2006), 1114–1122.
72. Chavakis, E., Urbich, C., Dimmeler, S., Homing and engraftment of progenitor cells: a prerequisite for cell therapy. J Mol Cell Cardiol 45 (2008), 514–522.
73. Zhang, M., Mal, N., Kiedrowski, M., Chacko, M., Askari, A.T., Popovic, Z.B., et al. SDF-1 expression by mesenchymal stem cells results in trophic support of cardiac myocytes after myocardial infarction. FASEB J 21 (2007), 3197–3207.
74. Prokoph, S., Chavakis, E., Levental, K.R., Zieris, A., Freudenberg, U., Dimmeler, S., et al. Sustained delivery of SDF-1α from heparin-based hydrogels to attract circulating pro-angiogenic cells. Biomaterials 33 (2012), 4792–4800.
75. Chung, E.S., Miller, L., Patel, A.N., Anderson, R.D., Mendelsohn, F.O., Traverse, J., et al. Changes in ventricular remodelling and clinical status during the year following a single administration of stromal cell-derived factor-1 non-viral gene therapy in chronic ischaemic heart failure patients: the STOP-HF randomized Phase II trial. Eur Heart J, 2015 pii: ehv254. [Epub ahead of print].
76. Hou, D., Youssef, E.A., Brinton, T.J., Zhang, P., Rogers, P., Price, E.T., et al. Radiolabeled cell distribution after intramyocardial, intracoronary, and interstitial retrograde coronary venous delivery: implications for current clinical trials. Circulation 112:Suppl. 9 (2005), I150–I156.
77. Brunskill, S.J., Hyde, C.J., Doree, C.J., Watt, S.M., Martin-Rendon, E., Route of delivery and baseline left ventricular ejection fraction, key factors of bone-marrow-derived cell therapy for ischaemic heart disease. Eur J Heart Fail 11 (2009), 887–896.
78. Medicetty, S., Wiktor, D., Lehman, N., Raber, A., Popovic, Z.B., Deans, R., et al. Percutaneous adventitial delivery of allogeneic bone marrow-derived stem cells via infarct-related artery improves long-term ventricular function in acute myocardial infarction. Cell Transplant 21 (2012), 1109–1120.
79. Behfar, A., Latere, J.P., Bartunek, J., Homsy, C., Daro, D., Crespo-Diaz, R.J., et al. Optimized delivery system achieves enhanced endomyocardial stem cell retention. Circ Cardiovasc Interv 6 (2013), 710–718.
80. Skuk, D., Goulet, M., Tremblay, J.P., Intramuscular transplantation of myogenic cells in primates: importance of needle size, cell number, and injection volume. Cell Transplant 23 (2014), 13–25.
81. Nelson, D.M., Ma, Z., Fujimoto, K.L., Hashizume, R., Wagner, W.R., Intra-myocardial biomaterial injection therapy in the treatment of heart failure: materials, outcomes and challenges. Acta Biomater 7 (2011), 1–15.
82. Hastings, C.L., Roche, E.T., Ruiz-Hernandez, E., Schenke-Layland, K., Walsh, C.J., Duffy, G.P., Drug and cell delivery for cardiac regeneration. Adv Drug Deliv Rev 84 (2015), 85–106.
83. Ban, K., Park, H.J., Kim, S., Andukuri, A., Cho, K.W., Hwang, J.W., et al. Cell therapy with embryonic stem cell-derived cardiomyocytes encapsulated in injectable nanomatrix gel enhances cell engraftment and promotes cardiac repair. ACS Nano 8 (2014), 10815–10825.
84. Godier-Furnémont, A.F., Martens, T.P., Koeckert, M.S., Wan, L., Parks, J., Arai, K., et al. Composite scaffold provides a cell delivery platform for cardiovascular repair. Proc Natl Acad Sci U S A 108 (2011), 7974–7979.
85. Hamdi, H., Furuta, A., Bellamy, V., Bel, A., Puymirat, E., Peyrard, S., et al. Cell delivery: intramyocardial injections or epicardial deposition?. A head-to-head comparison. Ann Thorac Surg 87 (2009), 1196–1203.
86. Aguado, B.A., Mulyasasmita, W., Su, J., Lampe, K.J., Heilshorn, S.C., Improving viability of stem cells during syringe needle flow through the design of hydrogel cell carriers. Tissue Eng Part A 18 (2012), 806–815.
87. Hamdi, H., Planat-Benard, V., Bel, A., Puymirat, E., Geha, R., Pidial, L., et al. Epicardial adipose stem cell sheets results in greater post-infarction survival than intramyocardial injections. Cardiovasc Res 91 (2011), 483–491.
88. Sekine, H., Shimizu, T., Dobashi, I., Matsuura, K., Hagiwara, N., Takahashi, M., et al. Cardiac cell sheet transplantation improves damaged heart function via superior cell survival in comparison with dissociated cell injection. Tissue Eng Part A 17 (2011), 2973–2980.
89. Fathi, E., Nassiri, S.M., Atyabi, N., Ahmadi, S.H., Imani, M., Farahzadi, R., et al. Induction of angiogenesis via topical delivery of basic-fibroblast growth factor from polyvinyl alcohol-dextran blend hydrogel in an ovine model of acute myocardial infarction. J Tissue Eng Regen Med 7 (2013), 697–707.
90. Shimizu, T., Yamato, M., Kikuchi, A., Okano, T., Cell sheet engineering for myocardial tissue reconstruction. Biomaterials 24 (2003), 2309–2316.
91. Padalino, M.A., Quarti, A., Angeli, E., Frigo, A.C., Vida, V.L., Pozzi, M., et al. Early and mid-term clinical experience with extracellular matrix scaffold for congenital cardiac and vascular reconstructive surgery: a multicentric Italian study. Interact Cardiovasc Thorac Surg 21 (2015), 40–49.
92. Seif-Naraghi, S.B., Singelyn, J.M., Salvatore, M.A., Osborn, K.G., Wang, J.J., Sampat, U., et al. Safety and efficacy of an injectable extracellular matrix hydrogel for treating myocardial infarction. Sci Transl Med, 5, 2013, 173ra25.
93. Pashuck, E.T., Stevens, M.M., Designing regenerative biomaterial therapies. Sci Transl Med, 4, 2012, 160sr4.
94. Harrison, R.H., St-Pierre, J.P., Stevens, M.M., Tissue engineering and regenerative medicine: a year in review. Tissue Eng Part B Rev 20 (2014), 1–16.
95. Hirt, M.N., Hansen, A., Eschenhagen, T., Cardiac tissue engineering: state of the art. Circ Res 114 (2014), 354–367.
96. Stoppel, W.L., Ghezzi, C.E., McNamara, S.L., Black, L.D., 3rd, Kaplan, D.L., Clinical applications of naturally derived biopolymer-based scaffolds for regenerative medicine. Ann Biomed Eng 43 (2015), 657–680.
97. Neuss, S., Apel, C., Buttler, P., Denecke, B., Dhanasingh, A., Ding, X., et al. Assessment of stem cell/biomaterial combinations for stem cell-based tissue engineering. Biomaterials 29 (2008), 302–313.
98. Tallawi, M., Rosellini, E., Barbani, N., Cascone, M.G., Rai, R., Saint-Pierre, G., et al. Strategies for the chemical and biological functionalization of scaffolds for cardiac tissue engineering: a review. J R Soc Interface, 12, 2015, 20150254.
99. Ifkovits, J.L., Tous, E., Minakawa, M., Morita, M., Robb, J.D., Koomalsingh, K.J., et al. Injectable hydrogel properties influence infarct expansion and extent of postinfarction left ventricular remodeling in an ovine model. Proc Natl Acad Sci U S A 107 (2010), 11507–11512.
100. Moya, M.L., Hsu, Y.H., Lee, A.P., Hughes, C.C., George, S.C., In vitro perfused human capillary networks. Tissue Eng Part C Methods 19 (2013), 730–737.
101. Novosel, E.C., Kleinhans, C., Kluger, P.J., Vascularization is the key challenge in tissue engineering. Adv Drug Deliv Rev 63 (2011), 300–311.
102. Stevens, K.R., Kreutziger, K.L., Dupras, S.K., Korte, F.S., Regnier, M., Muskheli, V., et al. Physiological function and transplantation of scaffold-free and vascularized human cardiac muscle tissue. Proc Natl Acad Sci U S A 106 (2009), 16568–16573.
103. Derby, B., Printing and prototyping of tissues and scaffolds. Science 338 (2012), 921–926.
104. Anker, S.D., Coats, A.J., Cristian, G., Dragomir, D., Pusineri, E., Piredda, M., et al. A prospective comparison of alginate-hydrogel with standard medical therapy to determine impact on functional capacity and clinical outcomes in patients with advanced heart failure (AUGMENT-HF trial). Eur Heart J, 2015 pii: ehv259 [Epub ahead of print].
105. Segers, V.F., Lee, R.T., Local delivery of proteins and the use of self-assembling peptides. Drug Discov Today 12 (2007), 561–568.
106. Kupfer, M.E., Ogle, B.M., Advanced imaging approaches for regenerative medicine: emerging technologies for monitoring stem cell fate in vitro and in vivo. Biotechnol J, 2015, 10.1002/biot.201400760 [Epub ahead of print].
107. Moudgil, R., Dick, A.J., Regenerative cell imaging in cardiac repair. Can J Cardiol 30 (2014), 1323–1334.
108. Smith, D.M., Assessing commercial opportunities for autologous and allogeneic cell-based products. Regen Med 7 (2012), 721–732.
109. Lohan, P., Coleman, C.M., Murphy, J.M., Griffin, M.D., Ritter, T., Ryan, A.E., Changes in immunological profile of allogeneic mesenchymal stem cells after differentiation: should we be concerned?. Stem Cell Res Ther, 5, 2014, 99.
110. Sarić T., Frenzel, L.P., Hescheler, J., Immunological barriers to embryonic stem cell-derived therapies. Cells Tissues Organs 188 (2008), 78–90.
111. Pearl, J.I., Lee, A.S., Leveson-Gower, D.B., Sun, N., Ghosh, Z., Lan, F., et al. Short-term immunosuppression promotes engraftment of embryonic and induced pluripotent stem cells. Cell Stem Cell 8 (2011), 309–317.
112. Calderon, D., Prot, M., You, S., Marquet, C., Bellamy, V., Bruneval, P., et al. Control of immune response to allogeneic embryonic stem cells by CD3 antibody-mediated operational tolerance induction. Am J Transplant 16 (2016), 454–467.
113. Zhang, Q., Ichimaru, N., Higuchi, S., Cai, S., Hou, J., Fujino, M., et al. Permanent acceptance of mouse cardiac allografts with CD40 siRNA to induce regulatory myeloid cells by use of a novel polysaccharide siRNA delivery system. Gene Ther 22 (2015), 1–10.
114. Ferrer, I.R., Hester, J., Bushell, A., Wood, K.J., Induction of transplantation tolerance through regulatory cells: from mice to men. Immunol Rev 258 (2014), 102–116.
115. Dumont, C.M., Park, J., Shea, L.D., Controlled release strategies for modulating immune responses to promote tissue regeneration. J Control Release, 2015, 10.1016/j.jconrel.2015.08.014 pii: S0168-3659(15)30060-2 [Epub ahead of print].
116. Malliaras, K., Li, T.S., Luthringer, D., Terrovitis, J., Cheng, K., Chakravarty, T., et al. Safety and efficacy of allogeneic cell therapy in infarcted rats transplanted with mismatched cardiosphere-derived cells. Circulation 125 (2012), 100–112.
117. Jansen Of Lorkeers, S.J., Eding, J.E., Vesterinen, H.M., van der Spoel, T.I., Sena, E.S., Duckers, H.J., et al. Similar effect of autologous and allogeneic cell therapy for ischemic heart disease: systematic review and meta-analysis of large animal studies. Circ Res 116 (2015), 80–86.
118. Hare, J.M., Fishman, J.E., Gerstenblith, G., DiFede Velazquez, D.L., Zambrano, J.P., et al. Comparison of allogeneic vs autologous bone marrow–derived mesenchymal stem cells delivered by transendocardial injection in patients with ischemic cardiomyopathy: the POSEIDON randomized trial. JAMA 308 (2012), 2369–2379.
119. Celiz, A.D., Smith, J.G., Langer, R., Anderson, D.G., Winkler, D.A., Barrett, D.A., et al. Materials for stem cell factories of the future. Nat Mater 13 (2014), 570–579.
120. Dixon, J.E., Shah, D.A., Rogers, C., Hall, S., Weston, N., Parmenter, C.D., et al. Combined hydrogels that switch human pluripotent stem cells from self-renewal to differentiation. Proc Natl Acad Sci U S A 111 (2014), 5580–5585.
121. Buffington, D.A., Pino, C.J., Chen, L., Westover, A.J., Hageman, G., Humes, H.D., Bioartificial Renal Epithelial Cell System (BRECS): a compact, cryopreservable extracorporeal renal replacement device. Cell Med 4 (2012), 33–43.
122. Kamenova, K., Caulfield, T., Stem cell hype: media portrayal of therapy translation. Sci Transl Med, 7(278), 2015, 278ps4.
123. McMurray, J.J., Packer, M., Desai, A.S., Gong, J., Lefkowitz, M.P., Rizkala, A.R., et al. Angiotensin-neprilysin inhibition versus enalapril in heart failure. N Engl J Med 371 (2014), 993–1004.